CMS has lifted the non-coverage decision for PET imaging for oncologic procedures, allowing local Medicare administrators to make decisions about coverage. The ruling, however, does not apply to cardiac and neurologic uses. SNMMI and other groups had lobbied for a broader decision. The decision applies to use of C-11 choline and other PET imaging agents for oncologic applications. The ruling does not address PET agents FDG, NaF-18, ammonia N-13 and rubidium-82, which already have been addressed with coverage determinations.